Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/191092Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Pera, Joan | - |
| dc.contributor.author | Castaño, Julio | - |
| dc.contributor.author | Casamitjana, Joan | - |
| dc.contributor.author | Giorgetti, Alessandra | - |
| dc.contributor.author | Romero Moya, Damià | - |
| dc.date.accessioned | 2022-11-24T18:15:07Z | - |
| dc.date.available | 2022-11-24T18:15:07Z | - |
| dc.date.issued | 2022-09-03 | - |
| dc.identifier.issn | 1873-5061 | - |
| dc.identifier.uri | https://hdl.handle.net/2445/191092 | - |
| dc.description.abstract | Germline SAMD9 mutations are one of the most common alterations that predispose to pediatric myelodysplastic syndrome (MDS), a clonal disorder characterized by ineffective hematopoiesis, increasing the risk of developing acute myeloid leukemia (AML). Up to date, a disease model to study the role of SAMD9 mutation in MDS is still lacking. Here, we have generated a human induced pluripotent stem cell (hiPSC) line carrying SAMD9mut (p.I1567M), taking advantage of CRISPR/Cas9 system. As a result, the genetic engineered hiPSC line represent a new in vitro disease model to understand the impact of SAMD9 mutation at molecular and cellular level during hematopoiesis. | - |
| dc.format.extent | 6 p. | - |
| dc.format.mimetype | application/pdf | - |
| dc.language.iso | eng | - |
| dc.publisher | Elsevier B.V. | - |
| dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.scr.2022.102906 | - |
| dc.relation.ispartof | Stem Cell Research, 2022, vol. 64, p. 102906 | - |
| dc.relation.uri | https://doi.org/10.1016/j.scr.2022.102906 | - |
| dc.rights | cc-by (c) Pera, Joan et al., 2022 | - |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
| dc.source | Articles publicats en revistes (Patologia i Terapèutica Experimental) | - |
| dc.subject.classification | Cèl·lules mare | - |
| dc.subject.classification | Leucèmia mieloide | - |
| dc.subject.classification | Mutació (Biologia) | - |
| dc.subject.other | Stem cells | - |
| dc.subject.other | Myeloid leukemia | - |
| dc.subject.other | Mutation (Biology) | - |
| dc.title | Generation of heterozygous SAMD9 CRISPR/Cas9-edited iPSC line (ESi086-A-3), carrying I1567M mutation | - |
| dc.type | info:eu-repo/semantics/article | - |
| dc.type | info:eu-repo/semantics/publishedVersion | - |
| dc.identifier.idgrec | 726964 | - |
| dc.date.updated | 2022-11-24T18:15:07Z | - |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
| dc.identifier.pmid | 36087523 | - |
| Appears in Collections: | Articles publicats en revistes (Patologia i Terapèutica Experimental) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 726964.pdf | 2.76 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License
